Nasopharyngeal Cancer – Global Pipeline Review (H1 2019) by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type – ResearchAndMarkets.com

May 28, 2019 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Nasopharyngeal
Cancer – Pipeline Review, H1 2019”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Nasopharyngeal Cancer – Pipeline Review, H1 2019
provides comprehensive information on the therapeutics under development
for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key
players involved in therapeutic development for Nasopharyngeal Cancer
and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies/Universities/Institutes, the
molecules developed by Companies in Phase III, Phase II, Phase I,
IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 22, 10,
3, 10, 6 and 1 respectively. Similarly, the Universities portfolio in
Phase II, Phase I, Preclinical and Discovery stages comprises 6, 3, 7
and 1 molecules, respectively.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Nasopharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Nasopharyngeal
    Cancer (Oncology) by companies and universities/research institutes
    based on information derived from company and industry-specific
    sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
    activities.
  • The pipeline guide reviews key companies involved in Nasopharyngeal
    Cancer (Oncology) therapeutics and enlists all their major and minor
    projects.
  • The pipeline guide evaluates Nasopharyngeal Cancer (Oncology)
    therapeutics based on mechanism of action (MoA), drug target, route of
    administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Nasopharyngeal Cancer (Oncology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Nasopharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Nasopharyngeal Cancer (Oncology) pipeline depth and focus of
    Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Key Topics Covered

  1. Introduction
  2. Nasopharyngeal Cancer – Overview
  3. Therapeutics Development
  4. Therapeutics Assessment
  5. Companies Involved in Therapeutics Development
  6. Drug Profiles
  7. Dormant Projects
  8. Discontinued Products
  9. Product Development Milestones

Companies Mentioned

  • Advenchen Laboratories LLC
  • Ambrx Inc
  • Apollomics Inc
  • Argenx SE
  • Ascentage Pharma Group Corp Ltd
  • Atara Biotherapeutics Inc
  • AVEO Pharmaceuticals Inc
  • BeiGene Ltd
  • Biomics Biotechnologies Co Ltd
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Cell Medica Ltd
  • Eureka Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • FLX Bio Inc
  • Immunomic Therapeutics Inc
  • Incyte Corp
  • Innovent Biologics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Molecular Partners AG
  • Neonc Technologies Inc
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Otsuka Holdings Co Ltd
  • Oxford Vacmedix UK Ltd
  • PNP Therapeutics Inc
  • Shanghai Junshi Bioscience Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Soricimed Biopharma Inc
  • Systimmune Inc
  • Tessa Therapeutics Pte Ltd
  • Vectorite Biomedical Inc
  • Viracta Therapeutics Inc
  • Xencor Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/liecpf

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs